Please type your full address or zip code below.

Cancel Submit

Gladys P. Velarde, M.D., FACC, FAHA

Gladys P. Velarde, M.D., FACC, FAHA
Associate Professor
Department of Medicine
Division of Cardiology

Medical Director, Cardiovascular Women's Heart Program; Program Director, Cardiovascular Disease Fellowship

Specializes in Cardiovascular Disease

Speaks English and Spanish

Call Us   Request Appointment Online
  • <a href = '/cardiology/'>Cardiovascular Disease</a>
Board Certifications
  • Cardiovascular Disease
Professional Education
  • Medical Education: New York University, New York, NY, USA
  • Residency: Internal Medicine, Presbyterian Hospital, New York, NY, USA
  • Fellowship: Cardiovascular Disease, Boston City Hospital, Boston, MA, USA
  • Fellowship: Cardiovascular Disease, Mount Sinai School of Medicine, New York, NY, USA
  • Clinical Special Interests: Cardiovascular disease in women and special populations; preventive cardiology; echocardiography
  • Research Special Interests: Gender and ethnic differences in cardiovascular disease; metabolic syndrome; diastolic dysfunction

Search for publications by Gladys P. Velarde

Please note: The resulting entries may not reflect a complete or accurate listing for Gladys P. Velarde. Many journals are not indexed by PubMed, and there may be articles by other authors of the same name listed by this search.

30.290580 -81.617657 UF Health Cardiovascular Center – Emerson
Suite 120
4555 Emerson Street
Jacksonville, FL 32207

Appointment: (904) 383-1036
Referral: (904) 383-1036
Referral Fax: (904) 383-1775
30.347047 -81.664392 UF Health Cardiovascular Center – Jacksonville
5th Floor, Ambulatory Care Center
655 West 8th Street
Jacksonville, FL 32209

Appointment: (904) 383-1011
Referral: (904) 244-4198
Referral Fax: (904) 244-3553
30.484160 -81.633557 UF Health Cardiovascular Center – North
Suite 3600
15255 Max Leggett Parkway
Jacksonville, FL 32218

Appointment: (904) 383-1000
Referral: (904) 383-1000
Referral Fax: (904) 383-1411
Academic Office
GME Office
5th Floor, Ambulatory Care Center
655 West 8th Street
Jacksonville, FL 32209
Phone: (904) 244-3932
Fax: (904) 244-3629
GME Program Administrator
Karen M. Goodman
(904) 244-3932
  • IRMA 2014: Impact of Ranolazine on Inflammatory, Thrombogenic, Lipogenic, Biomarkers in Women with Angina and Metabolic Syndrome

    Purpose: More than 5 million women are living with chronic stable angina (CSA) today compared to 4 million men. Similarly more women than men are affected with the metabolic syndrome (MBS). MBS is a group of cardiovascular risk factors such as pre-hypertension, poorly controlled cholesterol, and poorly controlled glucose levels. The metabolic syndrome leads to an increased risk of cardiovascular disease and type 2 diabetes in apparently healthy individuals. It is associated with advanced vascular damage and poorer health outcomes in those with cardiovascular disease (CVD). The reason for this gender difference in angina and MBS is unclear. Ranolazine is a drug the Food and Drug Administration (FDA) has approved for the treatment of angina. It has also had favorable effects on glycemic control. The purpose of this study is to investigate the potential additional benefits of ranolazine in women with CVD and MBS and to evaluate the ability of ranolazine to decrease angina. Secondary, this study will look at certain biomarkers in a group of ethnically diverse women with CSA and with MBS.
See all clinical trials by Gladys P. Velarde